Uses of immunoconjugates targeting CD138

US9289509B2 · kind B2 · utility

Assignees

• Biotest AG · DE
• IMMUNOGEN, INC. · US

Inventors

• Frank Osterroth · Dietzenbach, DE
• Christoph Uherek · Seligenstadt, DE
• Christoph Bruecher · Eschborn, DE
• Benjamin Daelken · Frankfurt am Main, DE
• André Engling · Frankfurt, DE
• Thomas Haeder · Dreieich, DE
• Andrea Wartenberg-Demand · Linden, DE
• Gabriele Niemann · Walzbachtal, DE
• Chantal Zuber · Frankfurt am Main, DE
• Niklas Czeloth · Dreieich, DE
• Silke Aigner · Bischofswerda, DE
• Steffen Zeng · Munster, DE
• Gregor Schulz · Umkirch, DE

Key dates

• Filing date: May 5, 2010
• Grant date: Mar 22, 2016
• Expiry date: May 5, 2030

Classification

• Technology area (CPC B): Performing Operations; Transporting
• CPC primary: B82Y5/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.